The probiotic <i>Lactobacillus rhamnosus</i> BFE5264 and <i>Lactobacillus plantarum</i> NR74 promote cholesterol efflux and suppress inflammation in THP‐1 cells

Yoon, Hongsup; Ju, Jaehyun; Lee, Jieun; Park, Hyunjoon; Lee, Jungmin; Shin, H. K.; Holzapfel, Wilhelm H.; Park, Kun-young; Do, Myoung‐Sool

doi:10.1002/jsfa.5797

Cited by 29 publications

(18 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…rhamnosus BFE5264 and L . plantarum NR74 also promote cholesterol efflux and inhibit expression of inflammatory cytokines such as IL-1β and TNF-α, which are increased by LXR activation [ 33 ]. In particular, these two strains activated LXR and induced cholesterol efflux by promoting the expression of ABCA1 and ABCG1.…”

Section: Discussionmentioning

confidence: 99%

Lactobacillus acidophilus K301 Inhibits Atherogenesis via Induction of 24 (S), 25-Epoxycholesterol-Mediated ABCA1 and ABCG1 Production and Cholesterol Efflux in Macrophages

Hong

Kim

et al. 2016

PLoS ONE

View full text Add to dashboard Cite

Lactobacillus acidophilus species are well-known probiotics with the beneficial activity of regulating cholesterol levels. In this study, we showed that L. acidophilus K301 reduced the level of cholesterol through reverse transport in macrophages. L. acidophilus K301 upregulated the mRNA and protein levels of genes such as ATP-binding cassette A1 (ABCA1) and ATP-binding cassette G1 (ABCG1) under the control of liver X receptor (LXR), resulting in increased apoA-I-dependent cholesterol efflux in phorbol 12-myristate 13-acetate (PMA)-differentiated THP-1 cells. L. acidophilus K301 induced both ABCA1 and ABCG1 through the endogenous LXR agonist 24(S), 25-epoxcycholesterol, which is synthesized by intracellular cholesterol synthetic pathways. In vivo studies using L. acidophilus K301-treated ApoE-/- mice showed reduced accumulation of lipoproteins in the arterial lumen. The inhibitory effects of L. acidophilus K301 on accumulation of lipoprotein in atherosclerotic plaques were mediated by the induction of squalene reductase (SQLE) and oxidosqualene cyclase (OSC) and resulted in ABCA1-mediated cholesterol efflux. Taken together, our findings revealed that Lactobacillus acidophilus K301 regulates the expression of genes related to cholesterol reverse transport via the induction of endogenous LXR agonist, suggesting the therapeutic potential of Lactobacillus acidophilus K301 as an anti-atherosclerotic agent.

show abstract

Section: Discussionmentioning

confidence: 99%

Lactobacillus acidophilus K301 Inhibits Atherogenesis via Induction of 24 (S), 25-Epoxycholesterol-Mediated ABCA1 and ABCG1 Production and Cholesterol Efflux in Macrophages

Hong

Kim

et al. 2016

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…However, a clinical trial in patients over 65 years old found that the ox-LDL level is inversely proportional to the number of Lactobacilli [ 96 ]. In addition, Yoon et al found that Lactobacillus rhamnosus BFE5264 and Lactobacillus plantarum NR74 may block foam cell formation by cholesterol efflux and immune modulation in THP-1 macrophage cells [ 97 ].…”

Section: Introductionmentioning

confidence: 99%

The regulation of immune cells by Lactobacilli: a potential therapeutic target for anti-atherosclerosis therapy

et al. 2017

View full text Add to dashboard Cite

Atherosclerosis is an inflammatory disease regulated by several immune cells including lymphocytes, macrophages and dendritic cells. Gut probiotic bacteria like Lactobacilli have been shown immunomodificatory effects in the progression of atherogenesis. Some Lactobacillus stains can upregulate the activity of regulatory T-lymphocytes, suppress T-lymphocyte helper (Th) cells Th1, Th17, alter the Th1/Th2 ratio, influence the subsets ratio of M1/M2 macrophages, inhibit foam cell formation by suppressing macrophage phagocytosis of oxidized low-density lipoprotein, block the activation of the immune system with dendritic cells, which are expected to suppress the atherosclerosis-related inflammation. However, various strains can have various effects on inflammation. Some other Lactobacillus strains were found have potential pro-atherogenic effect through promote Th1 cell activity, increase pro-inflammatory cytokines levels as well as decrease anti-inflammatory cytokines levels. Thus, identifying the appropriate strains is essential to the therapeutic potential of Lactobacilli as an anti-atherosclerotic therapy.

show abstract

“…This strain reduced cholesterol uptake in Caco-2 cells by downregulating the expression of NPC1L1, a critical factor for intestinal cholesterol absorption (3), and increasing cholesterol efflux in CHO-K1 cells by promoting the expression of ATP-binding cassette transporter A1 (ABCA1) and ATP-binding cassette transporter G1 (ABCG1) (4). These genes are the target genes for the cholesterol homeostasis regulators LXRα and LXRβ.…”

Section: Genome Announcementmentioning

confidence: 99%

Complete Genome Sequence of Lactobacillus rhamnosus BFE5264, Isolated from Maasai Traditional Fermented Milk

Choi

Park

et al. 2017

Genome Announc

Self Cite

View full text Add to dashboard Cite

show abstract

The probiotic Lactobacillus rhamnosus BFE5264 and Lactobacillus plantarum NR74 promote cholesterol efflux and suppress inflammation in THP‐1 cells

Cited by 29 publications

References 30 publications

Lactobacillus acidophilus K301 Inhibits Atherogenesis via Induction of 24 (S), 25-Epoxycholesterol-Mediated ABCA1 and ABCG1 Production and Cholesterol Efflux in Macrophages

Lactobacillus acidophilus K301 Inhibits Atherogenesis via Induction of 24 (S), 25-Epoxycholesterol-Mediated ABCA1 and ABCG1 Production and Cholesterol Efflux in Macrophages

The regulation of immune cells by Lactobacilli: a potential therapeutic target for anti-atherosclerosis therapy

Complete Genome Sequence of Lactobacillus rhamnosus BFE5264, Isolated from Maasai Traditional Fermented Milk

Contact Info

Product

Resources

About